Cadila’s COVID-19 vaccine may arrive in third month of 2021, shares hit 52-week high

Cadila Healthcare’s share price touched a 52-week high in early trade. Zydus Cadila said it would apply for Phase 3 clinical trials of its experimental COVID-19 vaccine in December. The company plans to launch the vaccination by March 2021.

The stock open to grab a gain of 4.42% at Rs 441 against the previous close of Rs 422 on BSE. On an intraday high, the stock touched Rs 425.45, a rise of 7.13%.


In the last two days, the stock gained a rise of 7.28%. Cadila Healthcare share is trading higher than 5 days, 20 days, 50 days, 100 days, and 200 days moving averages.

The large-cap share has gained 76.54% and rose 77%, in one year. The market cap of the firm rose to Rs 46,017 crore.

The report said, “Will ascertain the safety, dose, and efficacy of the potential vaccine.” Zydus Cadila will submit the results of the Phase 2 trials next week.

The company’s vaccine candidate said that no safety concerns were observed during initial results from Phase 2 trials ZyCoV-D. The company aims to conduct Phase 3 trials on 39,000 participants.

The pharma firm reported an over four-fold jump in its consolidated net profit to Rs 473.4 crore in quarter 2 against Rs 107.2 crore net profit for the corresponding period of the previous financial year.